Cascade genetic screening in hereditary transthyretin amyloidosis: when early diagnosis becomes survival
- 16 April 2026
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (32) , 4477-4479
Abstract
No abstract availableFunding Information
- Instituto de Salud Carlos III (PI23/01180)
- Instituto de Salud Carlos III (PI24/02093)
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (16/11/00432)
- Pro-CNIC Foundation
- Severo Ochoa Centers of Excellence Program (CEX2020-001041-S)
This publication has 14 references indexed in Scilit:
- Impact of Genetic Testing Family Screening in Hereditary Transthyretin AmyloidosisJACC: Cardiooncology, 2025
- Amiloidosis hereditaria por transtirretina por la variante Val142Ile en EspañaRevista Espanola de Cardiologia, 2025
- Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicineEuropean Heart Journal, 2025
- Evaluation of the 2021 ESC Recommendations for Family Screening in Hereditary Transthyretin Cardiac AmyloidosisEuropean Journal of Heart Failure, 2024
- Resultados de un programa de cribado poblacional de amiloidosis hereditaria por transtirretinaRevista Espanola de Cardiologia, 2024
- Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in SpainAmyloid, 2022
- Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2021
- Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challengesHeart Failure Reviews, 2020
- Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers ofTTRgene mutations*Amyloid, 2019
- Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosisAmyloid, 2019